[Value of desensitization for reintroducing trimethoprim-sulfamethoxazole in hypersensitive patients with HIV infection].
The incremental administration of trimethoprim-sulfamethoxazole (i.e., desensitization) in previously hypersensitive HIV-infected patients has been evaluated to date in 7 studies involving more than 10 patients. These studies differ greatly from one to another according to the inclusion criteria, exclusion criteria, and desensitization procedure (duration, lagtime between 2 doses). The efficacy varies from 33% to 100% but one can expect success in 3 out of 4 patients whatever the duration of the desensitization procedure. Short procedures seem better than long ones from the compliance point of view. These different procedures have not been compared each other. The reputation of good tolerance of this procedure is challenged by the recent description of severe life-threatening systemic reaction. Subsequent contra-indications must be ruled out and this procedure must be supervised in hospital.
Caumes
E
E
Service des Maladies Infectieuses et Tropicales, Groupe Hospitalier Pitié-Salpêtrière, Paris.
D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D003888:Desensitization, Immunologic; D004342:Drug Hypersensitivity / Q000628:therapy*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
Intérêt de la désensibilisation pour réintroduire le triméthoprime-sulfaméthoxazole chez les patients intolérants et infectés par le VIH.